Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients
Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients
复制标题
DOI：
10.1200/jco.2005.03.2433
复制
发表时间：
2006-05-20
影响因子：
45.3
通讯作者：
Cavazzini, Luigi
中科院分区：
文献类型：
--
作者：
Lanza, Giovanni;Gafa, Roberta;Cavazzini, Luigi
目的评价DNA错配修复（MMR）状态在大量II期和III期结直肠癌患者中的预后意义。MMR状态之间的关系，辅助化疗，和临床outcome.Patients和MethodsThe研究包括718例结直肠腺癌（393期11和325期111）谁接受根治性手术切除。MMR状态通过MLH 1和MSH 2表达的免疫组织化学分析来确定。微卫星不稳定性（MSI）进行了评估，在363例患者使用单核苷酸和二核苷酸marker. Results 114（15. 9%）的癌表现出异常MMR蛋白（MMRP）表达（96 MLH 1阴性和18 MSH 2阴性），并被归类为MMRP阴性，而604肿瘤表现出正常的MLH 1/MSH 2免疫反应性（MMRP阳性）。MLH 1/MSH 2表达与MSI状态密切相关（P
PurposeTo evaluate the prognostic significance of DNA mismatch repair (MMR) status in a large series of stage II and III colorectal cancer patients. The relationship among MMR status, adjuvant chemotherapy, and clinical outcome was also investigated.Patients and MethodsThe study included 718 patients with colorectal adenocarcinoma (393 stage 11 and 325 stage 111) who underwent curative surgical resection. MMR status was determined by immunohistochemical analysis of MLH1 and MSH2 expression. Microsatellite instability (MSI) was assessed in 363 patients using mononucleotide and dinucleotide markers.ResultsOne hundred fourteen (15.9%) carcinomas showed abnormal MMR protein (MMRP) expression (96 MLH1 negative and 18 MSH2 negative) and were classified as MMRP negative, whereas 604 tumors demonstrated normal MLH1/MSH2 immunoreactivity (MMRP positive). MLH1/MSH2 expression was closely related to MSI status (P